HPV-16E6 can induce multiple site phosphorylation of p53

Oncology Reports

Volumn 21, Issue 2, 2009, Pages 371-377

  Zhang, Ge ^a,b   Sun, Lina ^a,c   Li, Zongfang ^a   Song, Tusheng ^a   Huang, Chen ^a   Zhang, Wanggang ^a  

^a XI'AN JIAOTONG UNIVERSITY   (China)

^b SHANXI MEDICAL UNIVERSITY   (China)

^c CHINESE CENTER FOR DISEASE CONTROL AND PREVENTION   (China)

Author keywords

E6; Human papillomavirus; P53; Phosphorylation

Indexed keywords

GREEN FLUORESCENT PROTEIN; PROTEIN E6; PROTEIN P53; SERINE; E6 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 16; HYBRID PROTEIN; ONCOPROTEIN; REPRESSOR PROTEIN;

ARTICLE; CELL LINE; CELL NUCLEUS; CONTROLLED STUDY; HUMAN; HUMAN CELL; HUMAN PAPILLOMAVIRUS TYPE 16; IMMUNOBLOTTING; IMMUNOFLUORESCENCE; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; PROTEIN TRANSPORT; WILD TYPE; CONFOCAL MICROSCOPY; FLUORESCENT ANTIBODY TECHNIQUE; GENETIC TRANSFECTION; GENETICS; IMMUNOHISTOCHEMISTRY; METABOLISM; PHOSPHORYLATION; PHYSIOLOGY; TUMOR CELL LINE; VIROLOGY; WESTERN BLOTTING;

BLOTTING, WESTERN; CELL LINE, TUMOR; CELL NUCLEUS; FLUORESCENT ANTIBODY TECHNIQUE; GREEN FLUORESCENT PROTEINS; HUMAN PAPILLOMAVIRUS 16; HUMANS; IMMUNOHISTOCHEMISTRY; MICROSCOPY, CONFOCAL; ONCOGENE PROTEINS, VIRAL; PHOSPHORYLATION; RECOMBINANT FUSION PROTEINS; REPRESSOR PROTEINS; TRANSFECTION; TUMOR SUPPRESSOR PROTEIN P53;

EID: 62849113123     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or_00000232     Document Type: Article

References (39)

1. Zur Hausen H: Papillomaviruses in human cancer. Cancer 59: 1692-1696, 1987.
2. Zheng ZM and Baker CC: Papillomavirus genome structure, expression, and post-transcriptional regulation. Front Biosci 11: 2286-2302, 2006.
3. Kehmeier E, Rühl H, Voland B, Stöppler MC, et al: Cellular steady-state levels of 'high risk' but not 'low risk' human papillomavirus (HPV) E6 proteins are increased by inhibition of proteasome-dependent degradation independent of their p53-and E6AP-binding capabilities. Virology 299: 72-87, 2002.
4. Lazo PA: The molecular genetics of cervical carcinoma. Br J Cancer 80: 2008-2018, 1999.
5. Hiraiwa A, Kiyono T, Segawa K, et al: Comparative study on E6 and E7 genes of some cutaneous and genital papillomaviruses of human origin for their ability to transform 3Y1 cells. Virology 192: 102-111, 1993.
6. Scheffner M, Werness BA, Huibregtse JM, et al: The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell 63: 1129-1136, 1990.
7. Kawamata Y, Mitsuhashi A, Unno Y, Kado S, Shino Y, Uesugi K, Eguchi O, Ishii J, Seki K, Sekiya S and Shirasawa H: HPV 16-E6-mediated degradation of intrinsic p53 is compensated by upregulation of p53 gene expression in normal cervical keratinocytes. Int J Oncol 21: 561-567, 2002.
8. Butz K, Shahabeddin L, Geisen C, Spitkovsky D, Ullmann A and Hoppe-Seyler F: Functional p53 protein in human papillomavirus-positive cancer cells. Oncogene 10: 927-936, 1995.
9. Yonezawa Y, Hada T, Uryu K, et al: Mechanism of cell cycle arrest and apoptosis induction by conjugated eicosapentaenoic acid, which is a mammalian DNA polymerase and topoisomerase inhibitor. Int J Oncol 30: 1197-1204, 2007.
10. Meek DW: The p53 response to DNA damage. DNA Repair 3: 1049-1056, 2004.
11. Kanellou P, Zaravinos A, Spandidos DA, et al: Genomic instability, mutations and expression analysis of the tumour suppressor genes p14(ARF), p15(INK4b), p16(INK4a) and p53 in actinic keratosis. Cancer Lett 264: 145-161, 2008.
12. Giannakakou P, Nakano M, Nicolaou KC, et al: Enhanced microtubule-dependent trafficking and p53 nuclear accumulation by suppression of microtubule dynamics. Proc Natl Acad Sci USA 99: 10855-10860, 2002.
13. Rahman-Roblick R, Hellman U, Becker S, et al: Proteomic identification of p53-dependent protein phosphorylation. Oncogene 27: 4854-4859, 2008.
14. Carlisi D, Vassallo B, Lauricella M, et al: Histone deacetylase inhibitors induce in human hepatoma HepG2 cells acetylation of p53 and histones in correlation with apoptotic effects. Int J Oncol 32: 177-184, 2008.
15. Lavin MF and Gueven N: The complexity of p53 stabilization and activation. Cell Death Differ 13: 941-950, 2006.
16. Unger T, Sionov RV, Moallem E, Yee CL, Howley PM, Oren M and Haupt Y: Mutations in serines 15 and 20 of human p53 impair its apoptotic activity. Oncogene 18: 3205-3212, 1999.
17. Shieh SY, Ikeda M, Taya Y and Prives C: DNA damage-induced phosphorylation of p53 alleviates inhibition by MDM2. Cell 91: 325-334, 1997.
18. Sakaguchi K, Sakamoto H, Lewis MS, Anderson CW, Erickson JW, Appella E and Xie D: Phosphorylation of serine 392 stabilizes the tetramer formation of tumor suppressor protein p53. Biochemistry 36: 10117-10124, 1997.
19. Steegenga WT, van der Eb AJ and Jochemsen AG: How phosphorylation regulates the activity of p53. J Mol Biol 263: 103-113, 1996.
20. Siliciano JD, Canman CE, Taya Y, Sakaguchi K, Appella E and Kastan MB: DNA damage induces phosphorylation of the amino terminus of p53. Genes Dev 11: 3471-3481, 1997.
21. Chehab NH, Malikzay A, Stavridi ES and Halazonetis TD: Phosphorylation of Ser-20 mediates stabilization of human p53 in response to DNA damage. Proc Natl Acad Sci USA 96: 13777-13782, 1999.
22. Finlan LE, Nenutil R, Ibbotson SH, Vojtesek B and Hupp TR: CK2-site phosphorylation of p53 is induced in DeltaNp63 expressing basal stem cells in UVB irradiated human skin. Cell Cycle 5: 2489-2494, 2006.
23. Shin YC, Nakamura H, Liang X, Feng P, Chang H, Kowalik TF and Jung JU: Inhibition of the ATM/p53 signal transduction pathway by Kaposi's sarcoma-associated herpesvirus interferon regulatory factor 1. J Virol 80: 2257-2266, 2006.
24. Li L, Guo L, Tao Y, Zhou S, Wang Z, Luo W, Hu D, Li Z, Xiao L, Tang M, Yi W, Tsao SW and Cao Y: Latent membrane protein 1 of Epstein-Barr virus regulates p53 phosphorylation through MAP kinases. Cancer Lett 255: 219-231, 2007.
25. Granja AG, Nogal ML, Hurtado C, Salas J, Salas ML, Carrascosa AL and Revilla Y: Modulation of p53 cellular function and cell death by African swine fever virus. J Virol 78: 7165-7174, 2004.
26. Li X and Coffino P: High-Risk human papillomavirus E6 protein has two distinct binding sites within p53, of which only one determines degradation. J Virol 70: 4509-4516, 1996.
27. Cinti C, Claudio PP, Luca AD, Cuccurese M, Howard CM, D'Esposito M, Paggi MG, Sala DL, Azzoni L, Halazonetis TD, Giordano A and Maraldi NM: A serine 37 mutation associated with two missense mutations at highly conserved regions of p53 affect pro-apoptotic genes expression in a T-lymphoblastoid drug resistant cell line. Oncogene 19: 5098-5105, 2000.
28. Damia G, Filiberti L, Vikhanskaya F, Carrassa L, Taya Y, D'incalci M and Broggini M: Cisplatinum and taxol induce different patterns of p53 phosphorylation. Neoplasia 3: 10-16, 2001.
29. Das KC and Dashnamoorthy R: Hyperoxia activates the ATR-Chk1 pathway and phosphorylates p53 at multiple sites. Am J Physiol Lung Cell Mol Physiol 286: L87-L97, 2004.
30. Hiramatsu K, Ogino T, Ozaki M and Okada S: Monochloramine inhibits ultraviolet B-induced p53 activation and DNA repair response in human fibroblasts. Biochim Biophys Acta 1763: 188-196, 2006.
31. Chen Y, Miao ZH, Zhao WM and Ding J: The p53 pathway is synergized by p38 MAPK signaling to mediate 11,11′-dideoxyverticillin-induced G2/ M arrest. FEBS Lett 579: 3683-3690, 2005.
32. Pabla N, Huang S, Mi QS, Daniel R and Dong Z: ATR-Chk2 signaling in p53 activation and DNA damage response during cisplatin-induced apoptosis. J Biol Chem 283: 6572-6583, 2008.
33. Craig AL, Burch L, Vojtesek B, Mikutowska J, Thompson A and Hupp TR: Novel phosphorylation sites of human tumour suppressor protein p53 at Ser20 and Thr18 that disrupt the binding of mdm2 (mouse double minute 2) protein are modified in human cancers. Biochem J 342: 133-141, 1999.
34. Saito S, Yamaguchi H, Higashimoto Y, Chao C, Xu Y, Fornace AJ Jr, Appella E and Anderson CW: Phosphorylation site interdependence of human p53 post-translational modifications in response to stress. J Biol Chem 278: 37536-37544, 2003.
35. Sayed M, Pelech S, Wong C, Marotta A and Salh B: Protein kinase CK2 is involved in G2 arrest and apoptosis following spindle damage in epithelial cells. Oncogene 20: 6994-7005, 2001.
36. Blaydes JP and Hupp TR: DNA damage triggers DRB-resistant phosphorylation of human p53 at the CK2 site. Oncogene 17: 1045-1052, 1998.
37. Hupp TR and Lane DP:Two distinct signaling pathways activate the latent DNA binding function of p53 in a casein kinase II-independent manner. J Biol Chem 270: 18165-18174, 1995.
38. Wallace M, Coates PJ, Wright EG and Ball KL: Differential posttranslational modification of the tumour suppressor proteins Rb and p53 modulate the rates of radiation-induced apoptosis in vivo. Oncogene 20: 3597-3608, 2001.
39. Hao M, Lowy AM, Kapoor M, Deffie A, Liu G and Lozano G: Mutation of phosphoserine 389 affects p53 function in vivo. J Biol Chem 271: 29380-29385, 1996.